Silence Therapeutics plc Operating Cash Flow
Silence Therapeutics plc (SLN) reported Operating Cash Flow of -$14.09 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-10
- Silence Therapeutics plc net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $1.52M.
- Silence Therapeutics plc net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$15.60M.
- Silence Therapeutics plc net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$17.29M.
- Silence Therapeutics plc net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$10.89M.
- Silence Therapeutics plc net cash provided by (used in) operating activities for fiscal 2025 was -$62.27M.
- Silence Therapeutics plc net cash provided by (used in) operating activities for fiscal 2024 was -$67.64M.
- Silence Therapeutics plc net cash provided by (used in) operating activities for fiscal 2023 was -$49.46M.
- Silence Therapeutics plc net cash provided by (used in) operating activities for fiscal 2022 was -$57.04M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$14.09M 10-Q · filed 2026-08-10 | -$31.37M derived: sum of 3 quarters · filed 2026-08-10 | -$42.26M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$15.60M 10-Q · filed 2026-05-07 | -$32.89M derived: sum of 2 quarters · filed 2026-05-07 | -$43.78M derived: sum of 3 quarters · filed 2026-05-07 | -$65.56M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$17.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$28.18M derived: sum of 2 quarters · filed 2026-03-05 | -$49.96M derived: sum of 3 quarters · filed 2026-08-10 | -$62.27M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$10.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$32.67M derived: sum of 2 quarters · filed 2026-08-10 | -$44.98M 10-Q · filed 2025-11-06 | -$72.47M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$21.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$34.09M 10-Q · filed 2026-08-10 | -$61.57M derived: sum of 3 quarters · filed 2026-08-10 | -$87.18M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$12.31M 10-Q · filed 2026-05-07 | -$39.79M derived: sum of 2 quarters · filed 2026-05-07 | -$65.40M derived: sum of 3 quarters · filed 2026-05-07 | -$70.81M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$27.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$53.09M derived: sum of 2 quarters · filed 2026-03-05 | -$58.50M derived: sum of 3 quarters · filed 2026-03-05 | -$67.64M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$25.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$31.02M derived: sum of 2 quarters · filed 2025-11-06 | -$40.16M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | -$5.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$14.55M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | -$9.14M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | -$49.46M 10-K · filed 2025-02-27 | |||
| 2022-12-31 | -$57.04M 10-K · filed 2025-02-27 |